Bendamustine Hydrochloride Injection is an alkylating drug indicated for the treatment of adult patients with:
- Chronic lymphocytic leukemia (CLL): Efficacy relative to first-line therapies other than chlorambucil has not been established.
- Indolent B-cell non-Hodgkin lymphoma (NHL): This is indicated for cases that have progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Dosage and Side Effects
- Dosage: 100 mg/m² infused intravenously over 10 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles.
- Dosage: 120 mg/m² infused intravenously over 10 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles.
The common side effects of Bendamustine are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.
What is a bendamustine injection used for?
Bendamustine injection is used to treat chronic lymphocytic leukemia (CLL, cancer of white blood cells) and indolent B-cell non-Hodgkin’s lymphoma (NHL) in patients who have already received other treatments. It interferes with the growth of cancer cells, which are eventually destroyed by the body.
What type of therapy is bendamustine?
Bendamustine is a chemotherapy drug.
Is bendamustine safe to use?
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.
What is the side effect of bendamustine?
Most common side effects include: fatigue, fever, nausea, and vomiting, diarrhea, constipation, loss of appetite, cough, headache, weight loss, difficulty breathing, rash, mouth irritation, low red blood cells (oxygen-carrying cells), low platelets (blood-clotting cells), and decreased number of three different types
Is bendamustine FDA approved?
The drug Bendamustine was approved in October 2008 by the US FDA.